ResMed Inc (LTS:0KW4)
$ 248.625 -8.5249 (-3.32%) Market Cap: 36.23 Bil Enterprise Value: 36.66 Bil PE Ratio: 32.69 PB Ratio: 6.97 GF Score: 96/100

Resmed Inc at KeyBanc Capital Markets Life Sciences & Medtech Investor Forum (virtual) Transcript

Mar 23, 2021 / 08:15PM GMT
Release Date Price: $187.77
Matthew Ian Mishan
KeyBanc Capital Markets Inc., Research Division - VP & Senior Equity Research Analyst

All right. Good afternoon, and welcome to the last fireside chat of the day for the inaugural KeyBanc Life Sciences and Med Tech Investor Forum. My name is Matt Mishan. I'm a senior med tech analyst. I'm pleased to be joined by CFO, Brett Sandercock; and COO, Rob Douglas from ResMed. If you have any questions, there is a Q&A on the -- a Q&A box in the bottom of the screen that goes to me, and I'll do my best to get to them.

Questions & Answers

Matthew Ian Mishan
KeyBanc Capital Markets Inc., Research Division - VP & Senior Equity Research Analyst

So to start it off, Brett, Rob, how would you characterize the transition from December-January surge to kind of February-March vaccine optimism that we're starting to see?

Robert A. Douglas
ResMed Inc. - President & COO

Yes, Matt, I think in terms of the longer-term picture over the last year and through to where we are, we continue to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot